In the majority of cancers, secondary tumors (metastases) and associated complications are the main cause of death. To design the best therapy for a given patient, one of the major current challenge is to estimate, at diagnosis, the burden of invisible metastases and the future time of emergence of these, as well as their growth speed. In this talk, I will present the current state of our research efforts towards the establishment of a predictive computational tool for this aim. I will first shortly present the model used, which is based on a physiologically-structured partial differential equation for the time dynamics of the population of metastases, combined to a nonlinear mixed-effects model for statistical representation of the paramet...
International audienceDefining tumor stage at diagnosis is a pivotal point for clinical decisions ab...
International audienceTreating cancer patients with metastatic disease remains an ultimate challenge...
The dual classification of cancer as localized or metastatic disease is one of the key point in the ...
In the majority of cancers, secondary tumors (metastases) and associated complications are the main ...
In the majority of cancers, secondary tumors (metastases) and associated complications are the main ...
International audienceIn the majority of cancers, secondary tumors (metastases) and associated compl...
International audienceBrain metastases (BMs) are the largest disabling site for non-small cell lung ...
Rapid improvements in the detection and tracking of early-stage tumor progression aim to guide decis...
Mathematical modeling in cancer has been growing in popularity and impact since its inception in 193...
When cancer cells detach from an original tumor site to spread throughout the body, it is called met...
Treating cancer patients with metastatic disease remains an ultimate challenge in clinical...
International audienceDefining tumor stage at diagnosis is a pivotal point for clinical decisions ab...
International audienceTreating cancer patients with metastatic disease remains an ultimate challenge...
The dual classification of cancer as localized or metastatic disease is one of the key point in the ...
In the majority of cancers, secondary tumors (metastases) and associated complications are the main ...
In the majority of cancers, secondary tumors (metastases) and associated complications are the main ...
International audienceIn the majority of cancers, secondary tumors (metastases) and associated compl...
International audienceBrain metastases (BMs) are the largest disabling site for non-small cell lung ...
Rapid improvements in the detection and tracking of early-stage tumor progression aim to guide decis...
Mathematical modeling in cancer has been growing in popularity and impact since its inception in 193...
When cancer cells detach from an original tumor site to spread throughout the body, it is called met...
Treating cancer patients with metastatic disease remains an ultimate challenge in clinical...
International audienceDefining tumor stage at diagnosis is a pivotal point for clinical decisions ab...
International audienceTreating cancer patients with metastatic disease remains an ultimate challenge...
The dual classification of cancer as localized or metastatic disease is one of the key point in the ...